AIFA provides guidance on critical aspects relating to the management of clinical trials in Italy during the COVID-19 emergency

Published date16 March 2020
Subject MatterLife Sciences,China,EU,Clinical Trials,Crisis Management,Good Clinical Practices,Italy,Public Health,Infectious Diseases,Pharmaceutical Industry,Coronavirus/COVID-19
AuthorRiccardo Fruscalzo,Carlotta Busani
Law FirmHogan Lovells

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT